Latest stories on GKOS
Glaukos outlines $680M-$700M 2026 net sales as iDose TR seen at $275M-$280M
Seeking Alpha73 · bullishearnings
Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Glaukos Non-GAAP EPS of -$0.14 beats by $0.07, revenue of $185.6M beats by $34.69M
Seeking Alpha68 · bullishearnings
GLAUKOS Corp (GKOS) files 8-K
SEC 8-K50 · neutralgeneral
Glaukos Announces Second Quarter 2026 Financial Results | GKOS Stock News
StockTitan50 · neutralearnings
Glaukos: A Further Guidance Hike On Revenues Could Spike Shares Post Q2 Release
Seeking Alpha56 · neutralanalyst
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt | GKOS Stock News
StockTitan59 · neutralproduct/pr
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool57 · neutralanalyst
This Glaucoma Therapy Company Is Keeping An Eye On Profits
Investors.com63 · neutralanalyst
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 | GKOS Stock News
StockTitan50 · neutralgeneral
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis | GKOS Stock News
StockTitan63 · neutralproduct/pr
Glaukos Shareholders Reinforce Board, Pay and Auditor Support
TipRanks50 · neutralgeneral
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
Barron's66 · bullishanalyst